
Nephrolithiasis: Pathogenesis and Treatment



FREDRIÇ LAWRENCE COE JOAN HUNT PARKS

SECOND EDITION

Nephrolithiasis

Pathogenesis and Treatment

SECOND EDITION

Fredric Lawrence Coe, M.D.

Professor of Medicine and Physiology Head, Program in Nephrology University of Chicago Pritzker School of Medicine Chicago, Illinois

Joan Hunt Parks, M.B.A.

Research Associate, Department of Medicine University of Chicago Pritzker School of Medicine Chicago, Illinois



YEAR BOOK MEDICAL PUBLISHERS, INC. CHICAGO • LONDON • BOCA RATON

Copyright © 1978, 1988 by Year Book Medical Publishers, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. Printed in the United States of America.

2 3 4 5 6 7 8 9 0 Y R 92 91 90 89 88

Library of Congress Cataloging-in-Publication Data

Coe. Fredric L.

Nephrolithiasis: pathogenesis and treatment.

Includes bibliographies and index.

1. Kidneys—Calculi. I. Parks, Joan Hunt. II. Title. [DNLM: 1. Kidney Calculi—etiology. 2. Kidney Calculi—

therapy. WI 356 C672nl

RC916.C63 1988

616.6'22

87-22987

ISBN 0-8151-1801-5

Sponsoring Editor: Richard H. Lampert

Assistant Director, Manuscript Services: Frances M. Perveiler

Production Project Manager: Carol A. Reynolds

Proofroom Supervisor: Shirley E. Taylor

For our families

Eleanor Coe and Brian and Laura Coe and Gregory, Dana, and Leslie Parks

Preface: A Whim of the Tenth Moon

But while the moon is rounding towards the full He follows whatever whim's most difficult Among whims not impossible, . . . ¹

Imagine yourself writing a protocol for stone disease. You plan to measure what of blood and urine chemistry the causes of stones can distort, so that from what is abnormal or normal you can infer the probable cause and choose a treatment. Your protocol, constructed at leisure and over a long time, inspected by colleagues, drawn from what the most experienced or expert say is best to do, must exceed in verity—verity to what is thought best—what any doctor could contrive in practice. After all, a doctor can spend only so much of his time on one patient, or on the few he will encounter with stones, whereas someone who writes a protocol writes for everyone. He may set practice for a nation of doctors, and can afford, for a time, to give up to the effort the main energies of his life. Like the craft of one physician, the protocol tests itself and can be perfected. As patients are studied, their results confirm or disprove what is said in books they have certain kinds of abnormal traits, not others, for example and the protocol is changed to emphasize what is found. Because it is on paper the protocol forgets nothing, omits nothing, changes only as, and as much as what is known changes. It is a map in place of the explorer's rich, vague mind.*

Because it holds the truth, and can perfect itself, your protocol is full of promise, like a seed, and like a seed is lifeless by itself; it is a waking dream. Architect plans, musical scores, instructions for dance, scripts, medical protocols in turn, all are merely dreams, less than dreams because merely writings. The dreams become real only when people

^{*}These two enchanting adjectives were, of course, used by Yeats, who put them into the mouth of Cuchulain in his death speech to queen Aoife³; they referred, there, to the sea, with which Cuchulain had fought after he went mad toward the end of "On Baile's Strand."⁴ They are, through some foolishness, missing from the play in the author's own edition of 1934,⁴ and must be sought by those who would seek them where I say to look.³ Death of Cuchulain was added to the 1934 plays after Yeats had died, and the publisher used a text without either word.

who can perform what they say to do take them up and use them; and the shapes the dreams assume, the effects that they have upon people depend upon the performers, upon whether or not they are passionate, have talent, and love their craft.

Is your protocol all about measurement—as mine is? Then the quality of what the protocol becomes in life depends upon the laboratory. If the measurements are difficult, as they are, the laboratory must be special for them, committed to accuracy, and stable over the years so a measurement today can be compared to one made 10 years hence. Too stringent? Well, then, accept less for your patients. I have read how angry Sebastian Bach was with the choirboys at Leipzig who performed his weekly cantatas, though the results were music. I know a nephrologist and department chairman who can build a house, my coauthor in this book dances. I play piano, almost everyone reads plays; it is not hard to bring the dreams to life for oneself, but very hard to do it so it has its full effect—ideal care, for example—on others. Your protocol, being a dream and an ideal, must widen the difference between the best care and the ordinary, because a few will enact it with talent and passion, and others, most, perhaps, will—or must—content themselves with what is mundane: data that are imprecise, variable, and uncertain.

This vision of the dream and its performers, of the protocol and the laboratory, captivated me years ago, at the start of my career; and I, in thrall to the vision, set out to make a program in its image. I wrote protocols in Nephrology. I built a laboratory around a few excellent people who were excited by the vision and we began to enact my dream in our clinical theater. Doctors sent their patients. Data accumulated in our new charts. Letters and telephone calls began. The vision condensed into a material form. It took on the firmness of real life. And as it became real, the program displayed a size and complexity I had not imagined, that dawned upon me as an unwelcome revelation. Protocols were so complex, needed so many measurements, required so much scheduling, collating, calculating, comparing of results to normal results, keeping up of records, that I was unable to use them by myself and also be a doctor.

The complexity provoked a crisis; I needed more people, but I also wanted my program to support itself. Where was I to find the income within the program to pay for the people I needed? Medical fees could not support other people to help me; Universities need them to support their faculty, and doctors in practice for themselves. Grants for research are not for patient care. The only source was laboratory income, which by tradition goes almost always to hospitals or clinical pathologists,

not to the medical unit that cares for the patient; so I, with great reluctance, became the proponent of an unpopular cause. I cajoled, fought, wrangled, and argued with everyone who had authority and would listen, hospital managers, medical directors, deans, senior faculty, telling them that for the sake of an experiment the hospital corporation should give up money it considered its own. I fell by stages from dreamer to partisan to soldier to fanatic.

Ultimately, perhaps because the idea itself was irresistible, I got my way. The laboratory, the protocol, the doctor, and people to gather and maintain the information all came together into one unit that used its income to support itself; I called this mundane innovation of protocol, laboratory and staff, and altered financial arrangements wrested from an unwilling institution a 'Diagnostic Unit,' and made up my mind that to its development and proliferation I would devote my main energies. The idea of the unit was meant to be revolutionary, to create a change in medical practice; if units were built, and successful, others would follow.

Perhaps because I was young, somewhere between the first quarter moon and the full, or because I am by nature immoderate. I set out to reform all of Nephrology at once even though each protocol was daunting. The signs and symptoms of patients with kidney and urinary tract diseases group themselves into ten clusters, called syndromes,2 which doctors recognize by direct perception and simple testing; I wrote protocols for evaluating patients with each one. The first was for hypertension, common, serious, and due—sometimes—to curable causes detected by laboratory testing. Eric Reiss, Chairman of the Department of Medicine I then worked in, suggested stone disease as the second protocol. He thought the field of hypertension was a crowded one for a young clinical scholar, and knew that because most people were hypertensive for no obvious cause except heredity, the yield of causes from the protocol evaluation would be low. Stone disease is common. was studied then—as now—by only a small band of scientists, and has vielded up a rich harvest to those who before me had cultivated it. Besides that, Eric studied mineral metabolism and wanted company. I knew nothing about the diseases that cause stones, cared less, and ignored the idea; but after a few months, and on impulse, I decided to set up the measurements for a good stone laboratory.

For several years, my unit studied both patients with stones and patients with hypertension, and even began to study some—using the protocol method and the laboratory—who had primary renal diseases. Nephrology seemed small at that age, so why not do it all? I began to use a computer for the volumes of data we amassed; of course, patients

were plentiful. I soon responded to my computer's seductive nature: could not protocols be written into computer programs? My career itself gradually turned into an experiment: which of the protocols would work best? Would computers be useful? Would the whole idea prove important? Would I find that Nephrology was too small a field to be interesting, or too large to handle?

It is hard to place the exact time, but if the 14th moon is full it must have been near the tenth moon, or about when I was 35 that I decided to limit my work to stones. That decision was not rational. Partly, I was not publishing enough to stay in Academic Medicine; partly, no one believed I was anything but insane to work on so global an issue as the reform of an entire medical specialty; certainly, no agency wanted to fund research based on the units because plausibility was in doubt; perhaps I was guided by an instinct for self-preservation. Whatever the true cause—which I shall never know—I decided all at once, in an instant, to commit all of my energies to patients with stones, and I have continued to do this ever since.

The main question I pursued was unchanged, but limited to the one example of stone disease: was the unit idea a good one; would it be an important model for medical care? I thought of many tests I could use to find the answer, each a question of its own. Would a unit made of a protocol, a special laboratory, a doctor, and several others be practical, support itself, allow one doctor to do all of the clinical work and other things as well? Would we discover in most patients the diseases causing their stones? Would our diagnoses lead us to treatment that prevented stones? Would new clinical patterns display themselves?

Because I had begun to study only one problem, my interest in research increased; I saw how the unit could foster research. Since the laboratory, protocol, staff, and income were together; since the patients were studied uniformly in what was meant to be the best way possible; since the data were precise, stable, and accurate, and there was support for data collation, maintenance, and calculation, all that was needed to do research was to add people supported by research grants who could use the data. Since the unit was built to support itself, research subsidies could be much smaller, and the long-term stability of the unit for patient care much more certain than in a system for clinical research that depended mainly upon grants. I reasoned that if the unit proved attractive as a core for a funded center for research in stone disease, basic science work might gradually surround the clinical core because patients were available. It was, I suppose, simple chance that at about the right time the National Institutes of Health proposed funding a few

centers of stone research, and I know that it was our excellent fortune to win one.

By now, the moon has passed the full; the adventure and the dream are altered by experience. What the unit has contributed we have gathered here, in this volume, and we offer it up as the only answer we will ever have for all of our many questions. Will any other disease be like this one? Will any other people follow a whim so difficult, and will it be one that is possible? Is our result the curious outcome of a singular passion, or does it tell us that one part of medicine, that part which is about matters of craft, can be done like science is done and become part of science yet stay useful as medical practice? In all of our writings, we have never spoken of the unit itself, never about its real intent, about the whim and the dream; and we barely speak of it now, and only here, in this private and nearly invisible place.

FREDRIC L. COE

REFERENCES

- Yeats WB: The Phases of the Moon: The Poems of WB Yeats. New York, MacMillan Publishing Co, 1983, pp 163–167.
- Coe FL: Clinical and laboratory assessment of the patient with renal disease, in Brenner BM, Rector FC Jr (eds): The Kidney. Philadelphia, WB Saunders Co, 1986, pp 703–734.
- 3. Marcus PL: The Death of Cuchulain. Ithaca, NY, Cornell University Press, 1982, p 147.
- Yeats WB: On Baile's Strand: The Collected Plays of WB Yeats. New York, MacMillan Publishing Co, 1952, pp 162–182.

Acknowledgments

This book is for physicians who treat patients with renal stones and nephrocalcinosis. It is a comprehensive and practical book, personal and opinionated, and written in a style that is meant to please. The tables and figures summarize our own large experience of more than 1,400 patients, and compare what we have found to what is said by others. The references are as extensive and as complete as we could make them. We have written case reports of patients whose diseases are instructive because unusual. We have added a primer of mineral metabolism, stone radiographs and crystal photomicrographs, and a brief chapter on cystinuria, which was omitted from the first edition. The Preface is a story about how the Stone Program began, and what the results of its 17 years may mean about how medicine can be practiced.

Our colleagues elsewhere who study stone disease and mineral metabolism we have honored in the best way possible, by using their data, citing their papers, and arguing with their conclusions. Most of our collaborators in the program, in Chicago, speak for themselves, in their papers, which we quote liberally. We mention a few to whom our indebtedness is incalculable. Murray Favus and David Bushinsky study vitamin D and bone metabolism; Y. Nakagawa purified and has led our work on nephrocalcin, what we believe is the main urine inhibitor of calcium oxalate crystallization; Sergio DeGanello has given us what insights into crystallography we possess; Mary Soik Le Dunn has directed the Stone Laboratory almost since it opened, in 1969; Lisa Sandin is who our patients talk to most of the time.

Drs. Donald P. Griffith, Dennis J. Levinson, and Leif B. Sorenson contributed to or wrote chapters in the first edition on uric acid stones and struvite stones, and portions of what they wrote are retained here as a valued legacy. Much has changed, especially our own experience, so we have written—we hope as well as they did—what we now think and believe we know about the topics.

Although we suspect he rarely thinks about the matter, Dr. Franklin Epstein is the godfather of this book; he engendered its first edition by introducing me to its publishers and telling me to write it, he wrote its Foreword, and he edited the text. Dr. Nancy B. Cummings, when she was at the National Institutes of Health, established an initiative for specialized centers of research in stone disease, and we were fortunate

xiv / Acknowledgments

enough to win one of the five grant awards. The five centers brought together the few investigators who study this common illness, and made possible the creation of our mineral research group at Chicago. We who study stone disease are forever in debt to her vision.

Fredric Lawrence Coe Joan Hunt Parks

Contents

| Preface vii |
|---|
| 1 / Clinical Approach 1 |
| General Features 1 |
| Analysis of Kidney Stones 1 |
| Appearances of Kidney Stones 2 |
| Microscopic Appearance of Crystals 6 |
| Manifestations of Stone Disease 7 |
| Activity of Stone Disease: An Illustrative Case |
| Natural History of Stones 18 |
| Natural History in Selected Groups 19 |
| Causes of Stones 25 |
| Clinical and Laboratory Evaluation of Patients With |
| Stones 27 |
| Clinical History 28 |
| Physical Examination 31 |
| How to Decide Who Has Stones 31 |
| Laboratory Evaluation 32 |
| Sequence of Evaluation 34 |
| Something About Lithotripsy 35 |
| 2 / Physical Chemistry of Calcium Stone Disease 38 |
| Structure of Calcium Oxalate Monohydrate 39 |
| Supersaturation 42 |
| Basic Concepts 42 |
| Ion Concentrations 44 |
| Ions in Water 45 |
| Calculation of Supersaturation 46 |
| Empirical Measure of Supersaturation 47 |
| Heterogeneous Nucleation 49 |
| Clinical Nucleators 51 |
| Measurement of Nucleation in Urine 51 |
| Inhibitors 53 |
| Citrate 54 |
| Magnesium 54 |
| Pyrophosphate 54 |
| Glycoproteins 55 |

| Glycosaminoglycans 56 |
|--|
| 3 / Primary Hyperparathyroidism 59 Etiology of Primary Hyperparathyroidism 60 Regulation of Normal Parathyroid Hormone Secretion 60 Response to Chronic Hypocalcemia: Secondary Hyperparathyroidism 62 |
| Primary Hyperparathyroidism 62 |
| A Reasonable View of Etiology 64 |
| Normal Mineral Physiology 65 |
| Physiologic Effects of Parathyroid Hormone 65 |
| Parathyroid Hormone Effects on Bone 71 |
| Calcitriol Regulation 71 |
| Intestinal Transport 72 |
| General Features of Primary Hyperparathyroidism 72 |
| Blood and Urine Chemistry 72 |
| Observations in Our Patients 78 Biochemistry 78 |
| Biochemistry 78 Stone Disease 80 |
| Bone Disease 80 |
| Other Clinical Manifestations 83 |
| Association With Other Endocrine Abnormalities 83 |
| Diagnosis 84 |
| Establishment of Hypercalcemia 84 |
| Exclusion of Other Hypercalcemic States 84 |
| Role of Parathyroid Hormone and Urine Cyclic Adenosine |
| Monophospate Assays 88 |
| Ionized Calcium 88 |
| Other Measurements 88 |
| Normocalcemic Primary Hyperparathyroidism 89 |
| An Overview 89 |
| Surgical Treatment 90 |
| Localization Techniques 90 |
| Parathyroid Surgery 90 |
| Postoperative Care 94 |
| Long-Term Results 96 |
| Medical Treatment 99 |
| Choice of Patients 99 |
| Types of Treatment 99 |
| 4 / Familial (Idiopathic) Hypercalciuria 108 |
| Diagnosis and Occurrence 108 |
| What is Hypercalciuria? 108 |

| When is Hypercalciuria Idiopathic? 109 |
|---|
| Etiology 110 |
| Report of a Case 110 |
| Pathogenesis of Hypercalciuria 113 |
| Contrasting Theories 113 |
| Evidence for a Disorder of Calcitriol Metabolism 113 |
| Clinical Implications 116 |
| Unresolved Issues 119 |
| Clinical Features of Familial Hypercalciuria 122 |
| Laboratory Findings 123 |
| Clinical Consequences of Hypercalciuria 123 |
| Treatment 125 |
| Thiazide 125 |
| Low Calcium Diet 131 |
| Cellulose Phosphate 131 |
| Orthophosphate 131 |
| Magnesium 132 |
| / Calcium Phosphate Stones and Renal Tubular Acidosis 139 |
| Calcium Phosphate Stones in General 142 |
| Supersaturation With Respect to Calcium Phosphate |
| Salts 144 |
| Characteristics of Patients With Calcium Phosphate |
| Stones 144 |
| Clinical Features 144 |
| Laboratory Findings 145 |
| Normal Acid-Base Physiology 149 |
| Bicarbonate Equilibria 150 |
| Reclamation 153 |
| Normal Physiologic Variations of Urine pH 155 |
| Response to Alkali Loading 155 |
| Response to Acid Loading 156 |
| Renal Tubular Acidosis 157 |
| Types of Renal Tubular Acidosis 157 |
| Consequences of Distal Renal Tubular Acidosis 159 |
| Basic Defect in Distal Renal Tubular Acidosis 162 |
| Comparison of Proximal and Distal Renal Tubular |
| Acidosis 163 |
| Clinical Aspects of Renal Tubular Acidosis 165 |
| Incomplete Renal Tubular Acidosis 168 |
| / Hyperoxaluric States 172 |
| Types of Hyperoxaluria 172 |
| Consequences of Surplus Oxalate 174 |

xviii / Contents

| Hyperoxaluria 174 Systemic Oxalosis 175 Synthesis of Oxalate 178 Ascorbic Acid Pathway 178 | |
|--|-----|
| Glyoxylate Pathway 179 | |
| Summary 181 | |
| States of Oxalate Overproduction 182 | |
| Type I Hyperoxaluria 182 | |
| Type II Hyperoxaluria 183 | |
| Thiamine Deficiency 185 | |
| Pyridoxine Deficiency 185 | |
| Ethylene Glycol Ingestion 185 | |
| Methoxyflurane Anaesthesia 186 | |
| Treatment of Oxalate Overproduction 186 | |
| A Patient With Primary Hyperoxaluria 187 | |
| Absorptive Hyperoxaluria 187 | |
| Ileal Resection 188 | |
| Intestinal Bypass 190 | |
| Our Experience With Intestinal Disease and Stones | 192 |
| Dietary Oxalate Excess 192 | |
| Cellulose Phosphate 193 | |
| Patients With Dietary Hyperoxaluria 197 | |
| Treatment of Absorptive Hyperoxaluria 197 | |
| Clinical Overview of Hyperoxaluria 200 | |
| 7 / Uric Acid and Calcium Oxalate Stones 205 | |
| Mechanisms of Hyperuricosuria 206 | |
| Role of Diet 206 | |
| Role of Overproduction 207 | |
| Possible Renal Tubule Disturbance 208 | |
| Urine Supersaturation in Hyperuricosuric Patients | 210 |
| Clinical Features of Hyperuricosuric Calcium Oxalate | |
| Nephrolithiasis 212 | |
| Mixed Calcium Uric Acid Stone Disease 212 | |
| Interactions Between Calcium Oxalate and Uric Acid | |
| Crystals 214 | |
| Epitaxy 215 | |
| Heterogeneous Nucleation 217 | |
| Overview of Crystal Interactions 221 | |
| Reduced Urine Inhibitors 222 | |
| Allopurinol Treatment 224 | |
| | |
| Patients With Hyperuricosuria and Calcium Stones | 227 |

| Summary 228 |
|--|
| 8 / Idiopathic Stone Formers 232 Diagnostic Criteria 232 Excretion Rates 232 Supersaturation 233 Heterogeneous Nucleation 235 Inhibitors 235 Treatments 243 High Fluid Intake 243 Low Calcium Diet 243 Effect of Fluids and Low Calcium Intake 244 Orthophosphate 244 Thiazide and Allopurinol 247 |
| 9 / Uric Acid Stones 250 Factors That Control Uric Acid Crystallization 250 Urine pH 250 Uric Acid Excretion 255 Urine Volume 257 |
| Clinical Expression of Uric Acid Crystallization 258 Stones 258 Crystalluria 259 Obstruction 260 Clinical Settings for Uric Acid Stones 260 Idiopathic Uric Acid Stones 260 Gout 261 Neoplastic Diseases 262 Gastrointestinal Disease 262 Excessive Dermal Water Losses 262 Hyperuricosuria Without Hyperuricemia 263 Purine Gluttony 263 Treatment of Uric Acid Stones 263 Unusual Radiolucent Stones 265 |
| Pathogenesis of Cystinuria 269 Pathogenesis of Stones 270 Natural History 271 Treatment 272 Water 272 Alkali 272 Diet 272 |

xx / Contents

Index

294

D-Penicillamine 272 Thiola 274 Glutamine and Low Salt 274 11 / Struvite Stones 276 Pathogenesis and Etiology 276 Urea Hydrolysis Organisms With Urease 278 Clinical Course 278 General Experience 278 Our Experience 278 Treatments 284 Surgery 284 Lithotripsy 285 Medical Treatment 285 A View of Treatment 290